Lapatinib induced-changes in Caco-2 intestinal monolayer via ErbB1 inhibition / Raja Nur Firzanah Syaza Raja Sharin

Lapatinib (LAP) is an orally administered dual ErbBl and ErbB2 tyrosine kinase inhibitor for ErbB2-positive breast tumours, but is associated with diarrhoea. Incidence of lapatinib-induced diarrhoea (LID) is as high as 58-78% in treated patients. Although short-term diarrhoea is tolerable, prolonged...

Full description

Saved in:

Bibliographic Details
Main Author:	Raja Sharin, Raja Nur Firzanah Syaza
Format:	Thesis
Language:	English
Published:	2023
Subjects:	Cancer Individual drugs and other agents
Online Access:	https://ir.uitm.edu.my/id/eprint/91425/1/91425.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-uitm-ir.91425
record_format	uketd_dc
spelling	my-uitm-ir.914252024-02-28T22:02:11Z Lapatinib induced-changes in Caco-2 intestinal monolayer via ErbB1 inhibition / Raja Nur Firzanah Syaza Raja Sharin 2023 Raja Sharin, Raja Nur Firzanah Syaza Cancer Individual drugs and other agents Lapatinib (LAP) is an orally administered dual ErbBl and ErbB2 tyrosine kinase inhibitor for ErbB2-positive breast tumours, but is associated with diarrhoea. Incidence of lapatinib-induced diarrhoea (LID) is as high as 58-78% in treated patients. Although short-term diarrhoea is tolerable, prolonged diarrhoea can cause hospitalisation and interfere with cancer treatment, thus compromising the quality of life of patients with cancer. ErbBl is widely expressed in the intestine which functions to maintain homeostasis. Therefore, it is hypothesised that LAP inhibits ErbBl normal physiological in the intestine, leading to diarrhoea. This study aimed to investigate possible changes in Caco-2 intestinal monolayer following LAP treatment due to ErbB 1 inhibition. Several parameters such as intestinal permeability changes, alteration of tight junctions and intestinal inflammation due to ErbBl inhibition were studied using Caco-2 cells. Caco-2 is a colon cancer cell line, but it can differentiate into enterocytes and mimic normal intestinal cultures. Prior to Caco-2 differentiation, cytotoxic effect of LAP and LAP+recombinant epidermal growth factor (LAP+rEGF) on Caco-2 were evaluated at 24, 48, 72 and 96 hours using WST-1 assay. Caco-2 cells were seeded in a transwell insert for 21 days to form an intestinal epithelial monolayer prior to treatment. Monolayer integrity and permeability were assessed via transepithelial electrical resistance (TEER) and Lucifer yellow (LY) assay. 2023 Thesis https://ir.uitm.edu.my/id/eprint/91425/ https://ir.uitm.edu.my/id/eprint/91425/1/91425.pdf text en public masters Universiti Teknologi MARA (UiTM) Faculty of Medicine Wan Mohamad Zain, Wan Nor I'zzah
institution	Universiti Teknologi MARA
collection	UiTM Institutional Repository
language	English
advisor	Wan Mohamad Zain, Wan Nor I'zzah
topic	Cancer Individual drugs and other agents
spellingShingle	Cancer Individual drugs and other agents Raja Sharin, Raja Nur Firzanah Syaza Lapatinib induced-changes in Caco-2 intestinal monolayer via ErbB1 inhibition / Raja Nur Firzanah Syaza Raja Sharin
description	Lapatinib (LAP) is an orally administered dual ErbBl and ErbB2 tyrosine kinase inhibitor for ErbB2-positive breast tumours, but is associated with diarrhoea. Incidence of lapatinib-induced diarrhoea (LID) is as high as 58-78% in treated patients. Although short-term diarrhoea is tolerable, prolonged diarrhoea can cause hospitalisation and interfere with cancer treatment, thus compromising the quality of life of patients with cancer. ErbBl is widely expressed in the intestine which functions to maintain homeostasis. Therefore, it is hypothesised that LAP inhibits ErbBl normal physiological in the intestine, leading to diarrhoea. This study aimed to investigate possible changes in Caco-2 intestinal monolayer following LAP treatment due to ErbB 1 inhibition. Several parameters such as intestinal permeability changes, alteration of tight junctions and intestinal inflammation due to ErbBl inhibition were studied using Caco-2 cells. Caco-2 is a colon cancer cell line, but it can differentiate into enterocytes and mimic normal intestinal cultures. Prior to Caco-2 differentiation, cytotoxic effect of LAP and LAP+recombinant epidermal growth factor (LAP+rEGF) on Caco-2 were evaluated at 24, 48, 72 and 96 hours using WST-1 assay. Caco-2 cells were seeded in a transwell insert for 21 days to form an intestinal epithelial monolayer prior to treatment. Monolayer integrity and permeability were assessed via transepithelial electrical resistance (TEER) and Lucifer yellow (LY) assay.
format	Thesis
qualification_level	Master's degree
author	Raja Sharin, Raja Nur Firzanah Syaza
author_facet	Raja Sharin, Raja Nur Firzanah Syaza
author_sort	Raja Sharin, Raja Nur Firzanah Syaza
title	Lapatinib induced-changes in Caco-2 intestinal monolayer via ErbB1 inhibition / Raja Nur Firzanah Syaza Raja Sharin
title_short	Lapatinib induced-changes in Caco-2 intestinal monolayer via ErbB1 inhibition / Raja Nur Firzanah Syaza Raja Sharin
title_full	Lapatinib induced-changes in Caco-2 intestinal monolayer via ErbB1 inhibition / Raja Nur Firzanah Syaza Raja Sharin
title_fullStr	Lapatinib induced-changes in Caco-2 intestinal monolayer via ErbB1 inhibition / Raja Nur Firzanah Syaza Raja Sharin
title_full_unstemmed	Lapatinib induced-changes in Caco-2 intestinal monolayer via ErbB1 inhibition / Raja Nur Firzanah Syaza Raja Sharin
title_sort	lapatinib induced-changes in caco-2 intestinal monolayer via erbb1 inhibition / raja nur firzanah syaza raja sharin
granting_institution	Universiti Teknologi MARA (UiTM)
granting_department	Faculty of Medicine
publishDate	2023
url	https://ir.uitm.edu.my/id/eprint/91425/1/91425.pdf
_version_	1794192261441912832

Lapatinib induced-changes in Caco-2 intestinal monolayer via ErbB1 inhibition / Raja Nur Firzanah Syaza Raja Sharin

Similar Items